Description
Survodutide is a clinical-stage glucagon/GLP-1 dual receptor agonist in the same next-generation incretin family as mazdutide.
Its published trial focus leans toward liver outcomes — steatohepatitis endpoints alongside weight and glycemic measures — making it particularly relevant to hepatic-metabolism research.
Format & handling
Supplied as a lyophilized powder in a sealed, batch-stamped vial. Store sealed at −20 °C protected from light. For laboratory work, reconstitute with bacteriostatic water shortly before use and refrigerate any working solution at 2–8 °C.
For laboratory research use only — not for human or veterinary use. The summary above describes published research for scientific context and makes no claims about this product.
